Autoimmune hemolytic anemia (AIHA) occurs when your immune system produces antibodies that attack and destroy your own red blood cells faster than your bone marrow can replace them. The result is anemia — sometimes mild and slow-developing, sometimes severe enough to land you in the ICU. It affects roughly 1 to 3 per 100,000 people per year, with a peak incidence in adults over 40, though it can strike at any age, including childhood.
If you’re here because you or someone you know has been diagnosed — or you’re a clinician brushing up — this guide covers the actual mechanisms driving AIHA, the symptoms that should prompt urgent evaluation, how it’s diagnosed, and the treatment approaches backed by current evidence.
What Exactly Happens in AIHA?
Under normal circumstances, red blood cells (RBCs) live about 120 days before being recycled by the spleen and liver. In AIHA, autoantibodies — typically IgG or IgM — bind to proteins on the RBC surface and flag them for early destruction. The bone marrow tries to compensate by ramping up production (you’ll see this as reticulocytosis on labs), but when destruction outpaces production, hemoglobin drops and symptoms appear.
The destruction happens in two main ways:
- Extravascular hemolysis: IgG-coated RBCs are recognized and eaten by macrophages, primarily in the spleen. This is the dominant mechanism in warm AIHA.
- Intravascular hemolysis: IgM antibodies activate the complement cascade, literally punching holes in RBCs inside the bloodstream. This is the hallmark of cold agglutinin disease and can cause dramatic hemoglobinuria (dark or cola-colored urine).
Causes and Risk Factors for AIHA
About 50% of AIHA cases are primary (idiopathic) — meaning no underlying trigger is found. The other half are secondary to an identifiable cause. Here’s how they break down:
| Category | Examples | Notes |
|---|---|---|
| Autoimmune diseases | Systemic lupus erythematosus (SLE), rheumatoid arthritis, Sjögren’s syndrome | SLE is the most common autoimmune trigger; ~10% of SLE patients develop AIHA |
| Lymphoproliferative disorders | Chronic lymphocytic leukemia (CLL), non-Hodgkin lymphoma | Up to 10-25% of CLL patients develop AIHA during their disease course |
| Infections | Mycoplasma pneumoniae, Epstein-Barr virus, CMV, HIV, hepatitis C | Mycoplasma classically causes cold agglutinin disease in younger patients |
| Medications | Methyldopa, penicillin, cephalosporins, fludarabine, checkpoint inhibitors | Drug-induced AIHA typically resolves after stopping the offending agent |
| Post-transplant | Hematopoietic stem cell transplant, solid organ transplant | Often related to passenger lymphocyte syndrome or graft-vs-host dynamics |
A family history of autoimmune conditions increases susceptibility, and women are affected slightly more often than men in warm AIHA.
Symptoms of Autoimmune Hemolytic Anemia
Symptoms depend on how fast the hemolysis is occurring. A gradual onset may cause only mild fatigue, while an acute hemolytic crisis can be life-threatening. Here’s what to watch for:
General Anemia Symptoms
- Progressive fatigue and weakness
- Pallor (especially noticeable in the nail beds, conjunctivae, and palms)
- Shortness of breath on exertion
- Dizziness or lightheadedness
- Tachycardia (resting heart rate above 100 bpm)
Hemolysis-Specific Symptoms
- Jaundice — yellowing of the skin and eyes from elevated bilirubin
- Dark urine — ranging from tea-colored to cola-colored, reflecting hemoglobinuria or excess urobilinogen
- Splenomegaly — an enlarged spleen from working overtime to clear damaged RBCs
- Abdominal or back pain during acute hemolytic episodes
Cold Agglutinin Disease-Specific Symptoms
Patients with cold agglutinin disease (CAD) may also experience acrocyanosis (bluish discoloration of fingers, toes, ears, and nose in cold temperatures) and Raynaud’s phenomenon. Hemolytic crises can be triggered simply by cold exposure.
How AIHA Is Diagnosed
Diagnosis rests on three pillars: confirming anemia, proving it’s hemolytic, and demonstrating an autoimmune mechanism.
Key Laboratory Findings
| Test | Expected Finding in AIHA | Why It Matters |
|---|---|---|
| Hemoglobin | Low (often <10 g/dL, sometimes <6 g/dL in severe cases) | Confirms anemia |
| Reticulocyte count | Elevated (typically >2%) | Shows the bone marrow is responding — producing RBCs faster |
| LDH (lactate dehydrogenase) | Elevated | Released from destroyed RBCs |
| Indirect bilirubin | Elevated | Byproduct of hemoglobin breakdown |
| Haptoglobin | Low or undetectable | Haptoglobin binds free hemoglobin and gets cleared — a very sensitive marker of hemolysis |
| Direct antiglobulin test (DAT / Coombs test) | Positive | The cornerstone test — detects antibodies or complement on the RBC surface |
| Peripheral blood smear | Spherocytes, polychromasia | Spherocytes suggest splenic processing of antibody-coated RBCs |
The direct antiglobulin test (DAT), also called the direct Coombs test, is the single most important diagnostic test. A positive DAT for IgG suggests warm AIHA; a positive DAT for C3d (complement) alone points toward cold agglutinin disease. About 5-10% of AIHA cases are DAT-negative, which makes diagnosis more challenging and often requires referral to a hematologist.
Treatment and Management of AIHA
First-Line: Corticosteroids (Warm AIHA)
For warm AIHA, prednisone at 1-1.5 mg/kg/day remains the standard first-line therapy. Response rates are around 70-85%, with most patients showing improvement within 1-3 weeks. Once hemoglobin stabilizes, steroids are tapered slowly over several months. Rapid tapering is a common cause of relapse.
Second-Line Options
- Rituximab — an anti-CD20 monoclonal antibody that depletes B cells. Increasingly used early, especially when steroid-sparing is needed. Response rates of approximately 70-80% have been reported. Some centers now use rituximab alongside steroids as initial therapy.
- Splenectomy — removes the primary site of RBC destruction in warm AIHA. Effective in about 60-70% of patients, but carries long-term infection risks (particularly encapsulated organisms). Patients must be vaccinated against Streptococcus pneumoniae, Neisseria meningitidis, and Haemophilus influenzae beforehand.
- Immunosuppressants — azathioprine, mycophenolate mofetil, or cyclosporine for refractory cases.
Cold Agglutinin Disease: A Different Approach
CAD doesn’t respond well to steroids or splenectomy. The mainstay is cold avoidance and, when treatment is needed, rituximab (alone or combined with bendamustine). Sutimlimab, a complement C1s inhibitor, was FDA-approved in 2022 specifically for CAD — the first targeted therapy for this subtype. It works fast, with hemoglobin improvements often seen within the first week.
Transfusion Considerations
Blood transfusion in AIHA is tricky because autoantibodies can interfere with crossmatching. However, transfusion should never be withheld in life-threatening anemia. A specialized blood bank workup may be needed to identify the “least incompatible” units. Communicate early with your transfusion medicine team.
When to See a Doctor
Seek medical attention promptly if you experience:
- Unexplained fatigue that worsens over days to weeks
- Yellowing of the skin or eyes (jaundice)
- Dark or cola-colored urine, especially without dehydration
- Rapid heart rate, chest pain, or severe shortness of breath at rest — these suggest a hemoglobin level low enough to compromise oxygen delivery and warrant emergency evaluation
- New onset of cold-triggered blue fingers or toes
If you’ve already been diagnosed with AIHA, contact your hematologist if symptoms worsen during a steroid taper, after an infection, or if you develop fevers (which could signal infection in immunosuppressed patients).
FAQs About Autoimmune Hemolytic Anemia
Can AIHA go away on its own?
In some cases, yes — particularly in children and in cases triggered by a viral infection, AIHA can be self-limited. In adults, primary warm AIHA tends to be a chronic, relapsing condition. Around 20-30% of patients who respond to initial steroids will relapse and need second-line therapy.
Is AIHA life-threatening?
It can be. Acute, severe hemolytic crises can drop hemoglobin to dangerously low levels within hours. The overall mortality rate for AIHA is estimated at 3-10%, with higher rates in secondary AIHA (especially when linked to malignancy). Most patients, however, do well with appropriate treatment.
What’s the difference between warm and cold AIHA?
Warm AIHA (about 70-75% of cases) is driven by IgG antibodies that work at body temperature and primarily causes extravascular hemolysis in the spleen. Cold agglutinin disease (about 15-20% of cases) is driven by IgM antibodies that activate at temperatures below 37°C, causing complement-mediated intravascular hemolysis. Mixed-type AIHA accounts for the remainder. The distinction matters because they’re treated differently.
Can certain foods or supplements help with AIHA?
AIHA is an immune-mediated condition — no food or supplement can stop the antibody-driven RBC destruction. That said, folic acid supplementation (1 mg daily) is commonly recommended because the bone marrow is working overtime producing new red blood cells and needs adequate folate. Iron supplementation is generally not recommended unless a concurrent iron deficiency is documented, because the iron from destroyed RBCs is typically recycled.
Does having AIHA increase my risk for other autoimmune diseases?
Yes. AIHA is associated with a higher risk of developing other autoimmune conditions, including immune thrombocytopenia (ITP), thyroid disease, and SLE. When AIHA and ITP occur together, it’s called Evans syndrome, which can be particularly challenging to manage. Regular follow-up with a hematologist is essential.
